Bluebird bio and Regeneron Announce R&D and Commercialization Collaboration for Novel Cancer Immune Cell Therapies

 Bluebird bio and Regeneron Announce R&D and Commercialization Collaboration for Novel Cancer Immune Cell Therapies

Bluebird Bio and Gritstone Oncology signs a Research Collaboration

Shots: 

  • Collaboration is focused on using Regeneron’s Velocisuite platform for the discovery and characterization of human antibodies, T cell receptors and bluebird will contribute in gene transfer and cell therapy
  • The program has six initial targets with additional targets may be selected in five year term 50/50 R&D cost sharing till IND application. Regeneron has option to opt-in co-development/co-commercialization for certain undisclosed targets, with 50/50 cost and profit sharing. Regeneron to receive milestone payments and royalties in case of non-exercise of option on any potential resulting products 
  • Regeneron will also make a $100M investment in bluebird’s common stock at a price of $238.10/ share, at a premium of 59% on Aug 3, 2018. The premium includes ~$37M credited against Regeneron’s initial 50 % funding R&D collaboration 

Click here to read full press release/ article | Ref: Bluebird bio | Image: EHSCareers

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post